“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies

DOI: https://doi.org/10.1007/s40122-020-00171-7

[Section 1] This change in the approach to the treatment of low-frequency migraine is particu- larly important now that sufferers of high- frequency or chronic migraine need hospital access to be treated with a new pharmacological class of medications— monoclonal antibodies to calcitonin gene-related peptide (CGRP) or its receptor (CGRPr).

These are the patients who show fluctuations in the pre-chronic phase, with a high frequency of migraine crises, but who have not progressed to the stable chronic stage [191].

It is very important to resolutely limit the creeping trend of expanding the targets of this new pharmacological class of medications by also including patients with high-frequency migraine in the definition of chronicity [192].

4.2 Preventive Treatment

697

Such an inclusion would rapidly stress the spending sustainability of national health systems in general and also specifically penalize patients with chronic and pre-chronic migraine who have failed previous preventive therapies and who need priority access to these new treatments.

Acknowledgement A machine generated summary based on the work of Martelletti, Paolo. 2020  in Pain and Therapy.

InterMiG: international differences in the therapeutic approach to migraine patients in specialized headache centers